Novartis AG

Open: 100.98 Close: 101.03 Change: 0.05

The unbelievably easy way to evaluate Novartis AG Company Inc Stock: Use an AI.

This document will help you to evaluate Novartis AG without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Novartis AG are: AG, Novartis, company, pharmaceutical, form, Novartes, announce, …

Concept Map

Semantic Network

Stock Summary

Novartis AG researches, develops, manufactures, markets, markets healthcare products. The company operates through two segments: Innovative Medicines and Sandoz. Novarti has a license and collaboration agreement with Alnylam Pharmaceuticals.

Today's Summary

Novartis AG announced it has agreed to buy German biopharmaceutical company MorphoSys AG for 2.7 billion euros ($2.9 billion) The deal has already been approved by the boards of both companies.

Today's News

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel. The pharmaceutical and agrochemical divisions of both companies formed Novaris as an independent entity. In 1996, Ciba-Geigy merged with Sandoz, with the pharmaceuticals of both staying together to form Novarti. Novartis agreed to pay $678 million to settle allegations that the company violated the False Claims Act and Anti-Kickback Statute by paying physicians to induce them to prescribe certain of the companys drugs. Novartes filed for Exclusive Marketing Rights (EMR) for Gleevec in India in 1998. Federal prosecutors filed two lawsuits against Novartis under the False Claims Act for off-label marketing and kickbacks; in both suits, prosecutors are seeking treble damages. Outside the US, Novartes markets the drug ranibizumab (trade name Lucentis) outside US. Novartis announced that it has set its sights on MorphoSys with a $2.9bn cash acquisition agreement to bolster its oncology portfolio. Pelabresib is a selective, small-molecule bromodomain and extra-terminal domain (BET) inhibitor. Novartis AG announced it has agreed to buy German biopharmaceutical company MorphoSys AG for 2.7 billion euros ($2.9 billion) The deal has already been approved by the boards of both companies. The agreement, which is still subject to closing conditions, says that. Novartis was formed in 1996 from a merger of the two Basel pharmaceutical and chemical companies Ciba-Geigy AG and Sandoz AG. MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that it entered into a Business Combination Agreement with Novartes data42 AG and Novarts AG.

Stock Profile

"Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland."

Keywords

The game is changing. There is a new strategy to evaluate Novartis AG fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Novartis AG are: AG, Novartis, company, pharmaceutical, form, Novartes, announce, and the most common words in the summary are: novartis, company, ag, job, bloomberg, market, pharmaceutical, . One of the sentences in the summary was: Novartis AG announced it has agreed to buy German biopharmaceutical company MorphoSys AG for 2.7 billion euros ($2.9 billion) The deal has already been approved by the boards of both companies.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #novartis #company #ag #job #bloomberg #market #pharmaceutical.